Ripple,加密货币利益相关者就政策变化与白宫代表会面

币界网2024-08-09 tarihinde yayınlandı2024-08-09 tarihinde güncellendi

币界网报道:

拜登政府的顾问最近与包括Ripple和Coinbase高管在内的顶级加密货币利益相关者举行了电话会议。

在昨天的Zoom电话会议上,加密货币利益相关者对政府严格的监管政策表示担忧。尽管有人提出担忧,但拜登政府的顾问没有承诺任何政策变化。

白宫和加密货币参与者

与会者包括著名的加密货币高管,如Ripple首席执行官Brad Garlinghouse、SkyBridge的Anthony Scaramucci、Circle首席执行官Jeremy Allaire、Kraken首席执行官David Ripley、Uniswap首席执行官Hayden Adams以及美国顶级商人Mark Cuban和Chris Dixon。

另一方面,政府代表包括副总统立法事务主任Kristine Lucius、副幕僚长Bruce Reed、财政部副部长Wally Adeyemo、国家安全顾问Lael Brainard和其他知名官员。

彭博社声称已经看到了Zoom Call与会者的完整名单,据报道,Ripple发言人证实Garlinghouse和该公司董事长Chris Larsen参加了会议。

Ripple和Coinbase批评拜登严格的加密货币政策,

作为背景,Coinbase和Ripple公开批评了拜登政府的加密货币政策,称其为反创新。值得注意的是,这两家公司都是美国证券交易委员会执法行动的受害者。

美国证券交易委员会对Coinbase的诉讼仍处于早期阶段。然而,在最终判决发布后,Ripple的法律纠纷于本周在纽约南区结束。

民主党人试图吸引加密货币选民

随着该行业在美国面临严格的监管审查,其领导人希望通过在即将到来的选举中支持共和党的亲加密政治家来扭转局面。

有趣的是,前总统唐纳德·特朗普是加密货币爱好者的首选候选人。他的一些竞选承诺包括支持比特币挖矿和健全的行业政策。

因此,包括Ripple CLO Stuart Alderoty在内的加密货币爱好者为他的竞选活动提供了大量捐款。正如早些时候报道的那样,Alderoty以624000 XRP支持特朗普的竞选活动,价值约30万美元。

随着特朗普越来越多地得到加密货币利益相关者的支持,卡玛拉·哈里斯总统竞选组织者一直在不懈地努力重建民主党与该行业之间的关系。这导致了一系列会议,作为吸引加密货币选民努力的一部分。

上个月,Garlinghouse透露,加密货币高管与白宫代表举行了圆桌讨论。据他介绍,这次会议标志着将加密监管的言论转化为实际行动的第一步。

İlgili Okumalar

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

On August 10, 2026, BPL (300246.SZ) resumed trading after a nearly week-long suspension and immediately fell by a 20% limit-down. This plunge was triggered by the termination of a planned controlling stake transfer, dashing earlier market speculation. In January 2026, Zhejiang Quwei Zhihe Partnership entered as a significant shareholder, sparking hopes. Investors speculated that its backer, Weigu Information—a specialized "little giant" company in high-reliability solid-state storage chips—might be seeking a backdoor listing through BPL. This "cross-industry restructuring" expectation fueled a strong rally, with BPL's stock price more than doubling in 2026 prior to the halt. However, the deal was called off on August 7, directly causing the sharp sell-off. Underlying BPL's vulnerability is its fundamentally weak business. The company, a medical device firm, is mired in losses, having reported three consecutive years of net losses totaling over 200 million yuan. Its core hemodialysis business is squeezed by government procurement price cuts, while growth in its patient monitor segment has stalled. Furthermore, BPL faces imminent debt pressure with convertible bonds worth approximately 218 million yuan due in September 2026, and its current stock price is far below the conversion price. The failed control transfer may represent a delayed release of negative news, but BPL's core challenges remain: reversing operational losses and addressing its urgent liquidity crisis.

marsbit2 saat önce

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

marsbit2 saat önce

İşlemler

Spot
活动图片